Navigation Links
Self-Monitoring of Blood Thinner May Halve Clot Risk

By Steven Reinberg
HealthDay Reporter

WEDNESDAY, Nov. 30 (HealthDay News) -- People taking the blood-thinning drug warfarin who monitor their own blood and adjust their dosage can reduce the risk of blood clots by half, British researchers report.

Warfarin (Coumadin, Jantoven) is taken to prevent potentially deadly clots in patients with conditions such as atrial fibrillation -- an abnormal heart rhythm -- or a mechanical heart valve. But if the blood is thinned too much, serious bleeding can occur. Keeping the drug in check requires monthly monitoring and frequent doctors visits.

"The concept of self-care and self-monitoring is a growing part of health care it is used widely in diabetes, asthma and hypertension management," said lead researcher Dr. Carl Heneghan, director of the Center for Evidence-Based Medicine at the University of Oxford.

"The evidence shows that self-monitoring is an effective strategy to reduce thromboembolic events in patients taking oral anticoagulants such as warfarin," he added.

Self-monitoring of warfarin, a relatively inexpensive drug, involves using a meter similar to those diabetics use to monitor blood sugar. In this case, patients place a drop of blood from a finger prick on a test strip and insert the strip into the device, which reads what is called the international normalization ratio (INR).

If the INR is too high, risk of bleeding increases; if it is too low, there is an increased risk of stroke. Keeping the INR in the therapeutic range requires monthly checking and sometimes altering the dose of warfarin.

INR monitors cost $1,500 to $2,500, and test strips can run from $7 to $18, according to the National Blood Clot Alliance. Insurance coverage depends on the insurer and for which condition warfarin is taken.

In Germany, as many as 20 percent of those taking warfarin check their own blood and adjust their dosage accordingly, while in the United States only about 1 percent of similar patients do so, the researchers said.

The report appears in the Dec. 1 online edition of The Lancet.

For the study, Heneghan's team culled data from 11 studies that included about 6,400 patients, in a process called meta-analysis, which looks for patterns in previously published studies.

Each study compared self-monitoring with standard care, which involves blood tests done by doctors.

The researchers compared the two approaches in terms of deaths, major bleeding, deep vein thrombosis and stroke in patients with a variety of heart conditions.

The researchers found that self-monitoring reduced the risk of stroke or deep vein thrombosis by 49 percent, compared to standard care. However, it did not significantly alter the odds of a major bleed or death.

The greatest effect of self-monitoring was seen among those younger than 55, where the risk of stroke or deep vein thrombosis was cut by two-thirds.

In patients with mechanical heart valves, self-monitoring cut the risk of stroke or deep vein thrombosis by 50 percent, the researchers noted.

Among older patients, who are at risk for major bleeding, self-monitoring reduced the risk of dying and didn't increase the risk of complications.

The study received public funding from the U.K. National Institute for Health Research Technology Assessment Program.

Dr. Paul Alexander Kyrle, from the department of internal medicine at the Medical University of Vienna and co-author of an accompanying journal editorial, said "the effect of self-monitoring is not the same for all patient groups."

Whereas patients with mechanical heart valves benefit, especially men younger than 55, other patient groups, including those with atrial fibrillation, do not, he noted.

"There are now new oral anticoagulants on the market, which are at least as safe and effective as compared with warfarin, and they do not require regular coagulation monitoring. So many patients with atrial fibrillation will switch from warfarin to the new substances in the very near future," Kyrle said.

Another expert, Dr. Gregg Fonarow, associate chief of cardiology at the University of California, Los Angeles, agreed. More recent drugs such as rivaroxaban (Xarelto), apixaban (Eliquis) and dabigatran (Pradaxa) provide safe and effective anticoagulation without the need for any blood tests, he said. "Many patients requiring anticoagulation will find these new oral agents to be the most attractive option," Fonarow said.

More information

For more on warfarin, visit the U.S. National Library of Medicine.

SOURCES: Carl Heneghan, B.M., reader in evidence-based medicine, director, Center for Evidence-Based Medicine University of Oxford, U.K.; Paul Alexander Kyrle, M.D., Department of Internal Medicine, Medical University of Vienna, Austria; Gregg Fonarow, M.D., associate chief, cardiology, University of California, Los Angeles; Dec. 1, 2011, The Lancet, online

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Simple blood test diagnoses Parkinsons disease long before symptoms appear
2. Womens High Blood Sugar Linked to Colorectal Cancer: Study
3. High blood sugar levels in older women linked to colorectal cancer
4. Cell molecule identified as central player in the formation of new blood vessels
5. Newer Blood Thinner May Pose Danger to Trauma Patients
6. Life-threatening condition in preemies linked to blood type
7. At-Home Blood Pressure Readings Might Help Track Ailing Brain: Study
8. Molecules on branched-polymer surfaces can capture rare tumor cells in blood
9. Blood Type May Be Associated With Stroke Risk: Study
10. New screening method can detect a range of clinical conditions from a single dried blood spot
11. Blood disorders are a public health issue
Post Your Comments:
Related Image:
Self-Monitoring of Blood Thinner May Halve Clot Risk 
(Date:10/12/2017)... Del. (PRWEB) , ... October 12, 2017 , ... ... and advisory services for healthcare compliance program management, will showcase a range of ... National Association for Assisted Living (NCAL) Convention and Expo to be held October ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... products to meet the demand of today’s consumer and regulatory authorities worldwide. From ... probiotic experts and tested to meet the highest standard. , These products ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a ... health care, have expanded their existing home health joint venture through an agreement, ... been operating a joint venture home health company with Asante, delivering clinically integrated ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... HMP ... the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare ... City on October 11, 2017. , The annual award competition recognizes editorial and design ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand Rapids-based ... and Brightest in Wellness® by Best and Brightest. OnSite Wellness will be honored ... 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
(Date:9/28/2017)... CHICAGO , Sept. 28, 2017 Hill-Rom ... quarter 2017 earnings conference call and webcast on Friday, ... 8:00 a.m. (EDT) and ending at approximately 8:30 a.m. ... to discussing the company,s 2017 financial performance and guidance ... growth opportunities, initiatives to enhance operational performance, and long-range ...
(Date:9/25/2017)... 2017   Montrium , an industry leader ... the IQPC Trial Master Files & Inspection Readiness ... EastHORN Clinical Services has selected eTMF Connect ... management. EastHORN, a leading European contract research organization ... transparency to enable greater collaboration with sponsors, improve ...
Breaking Medicine Technology: